Related Experiment Videos
Heparin-Coated Coronary Stents.
van Der Giessen WJ1, van Beusekom HM, Larsson
1Thoraxcenter, Erasmus University, Dijkigt dr. Molewatersplein 40, 3015 GD Rotterdam, The Netherlands.
Current Interventional Cardiology Reports
|November 30, 2000
Summary
Heparin-coated stents show low thrombosis rates, even in acute coronary syndromes. While large trials are needed to confirm benefits over non-coated stents, they have advanced stent therapy in cardiology.
Area of Science:
- Interventional Cardiology
- Biomaterials Science
Background:
- Early bare-metal stents had unfavorable outcomes before advanced imaging and antiplatelet therapies.
- Heparin-coated (HC) stents were developed to improve safety and efficacy in coronary interventions.
Purpose of the Study:
- To evaluate the incidence of stent thrombosis with HC stents.
- To compare the efficacy of HC stents versus non-coated stents in challenging clinical scenarios.
Main Methods:
- Review of pilot and randomized trials involving HC stents.
- Preliminary comparison of available trial data.
Main Results:
- Pilot and randomized trials demonstrate a low incidence of (sub)acute stent thrombosis with HC stents, even in acute coronary syndromes.
- HC stents may be as effective as non-coated stents combined with abciximab therapy.
- HC stents have facilitated wider adoption of stent therapy in interventional cardiology.
Conclusions:
- Heparin-coated stents exhibit a low thrombosis rate, offering a safe option in complex cases.
- While definitive clinical superiority over non-coated stents requires further large-scale trials, HC stents have significantly contributed to the advancement of coronary stenting.
- The development of HC stents has played a crucial role in the increased utilization and acceptance of stent therapy for ischemic heart disease.